BioSpace News Archive

BioSpace caught up with Tara Frenkl and Nelson Ambrogio ahead of ASCO to discuss Bayer’s goal of becoming a top 10 oncology company by 2030.

The Phase I mechanism of action study, showing that Lilly’s injectable Mounjaro (tirzepatide) induces greater weight loss than placebo and Novo Nordisk’s semaglutide in adults with type 2 diabetes.

The Phase III ADvocate 1 and 2 studies on lebrikizumab showed that eight out of 10 patients with atopic dermatitis maintained skin clearance in the 12 months they had been under treatment.

Amarin and Vincerx Pharma intend to restructure their financial strategies and lessen operational costs by trimming their employee rosters.

For the first time in half a decade, the FDA will convene to address two therapies developed by bluebird bio that could have ripple effects across the industry regarding lentiviral vectors.

The Tisch MS Research Center of New York has been researching the concept of using cell therapy as a therapeutic strategy to promote repair and regeneration in certain patients with MS.

Alvotech Holdings S.A. and Oaktree Acquisition Corp. II announced that their previously announced business combination between Alvotech S.A., OACB and the legal entity named Alvotech, previously named Alvotech Lux Holdings S.A.S., with Alvotech as the surviving entity was approved by OACB shareholders at an Extraordinary General Meeting on June 7, 2022.

DermTech, Inc. announced the grant to one new employee of stock options to purchase an aggregate of 135,397 shares of the Company’s common stock at an exercise price of $6.35 per share and the grant to 28 new employees of restricted stock units representing the contingent right to receive up to an aggregate of 569,240 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, or the 2022 Inducement Plan.

Nyxoah SA is proud to announce that it is part of the newly-formed Euronext Tech Leaders initiative, which is composed of 100+ innovative and high-growth technology companies with greater than 1 trillion Euros in aggregate market capitalization.

The U.S. Food and Drug Administration has approved Dupixent® for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.